neoantigens cancer immunotherapy
clinical relevance t cells control diverse set human cancers now beyond doubt however nature antigens allow immune system distinguish cancer cells noncancer cells long remained obscure recent technological innovations made possible dissect immune response patient-specific neoantigens arise consequence tumor-specific mutations emerging data suggest recognition neoantigens major factor activity clinical immunotherapies observations indicate neoantigen load may form biomarker cancer immunotherapy provide incentive development novel therapeutic approaches selectively enhance t cell reactivity class antigens
